HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib

被引：0
|
作者：
Garrett, Joan T. [1 ]
Becker, Jennifer [1 ]
Estrada, Monica Valeria [1 ]
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-LB-212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-212
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
    Hanker, Ariella B.
    Garrett, Joan T.
    Estrada, Monica Valeria
    Moore, Preston D.
    Ericsson, Paula Gonzalez
    Koch, James P.
    Langley, Emma
    Singh, Sharat
    Kim, Phillip S.
    Frampton, Garrett M.
    Sanford, Eric
    Owens, Philip
    Becker, Jennifer
    Groseclose, M. Reid
    Castellino, Stephen
    Joensuu, Heikki
    Huober, Jens
    Brase, Jan C.
    Majjaj, Samira
    Brohee, Sylvain
    Venet, David
    Brown, David
    Baselga, Jose
    Piccart, Martine
    Sotiriou, Christos
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4323 - 4334
  • [2] HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 (vol 23, pg 4323, 2017)
    Hanker, Ariella B.
    Garrett, Joan T.
    Estrada, Monica Valeria
    Moore, Preston D.
    Ericsson, Paula Gonzalez
    Koch, James P.
    Langley, Emma
    Singh, Sharat
    Kim, Phillip S.
    Frampton, Garrett M.
    Sanford, Eric
    Owens, Philip
    Becker, Jennifer
    Groseclose, M. Reid
    Castellino, Stephen
    Joensuu, Heikki
    Huober, Jens
    Brase, Jan C.
    Majjaj, Samira
    Brohee, Sylvain
    Venet, David
    Brown, David
    Baselga, Jose
    Piccart, Martine
    Sotiriou, Christos
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1434 - 1434
  • [3] Lapatinib for the treatment of HER2-overexpressing breast cancer
    Jones, J.
    Takeda, A.
    Picot, J.
    von Keyserlingk, C.
    Clegg, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 1 - 6
  • [4] Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models
    Albrecht, Huguette
    IMMUNOTHERAPY, 2010, 2 (06) : 795 - 798
  • [5] Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
    Gayle, Sylvia S.
    Arnold, Samuel L. M.
    O'Regan, Ruth M.
    Nahta, Rita
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (02) : 151 - 162
  • [6] Effects of trastuzumab and paclitaxel in HER2-overexpressing breast cancer
    Li, Songhua
    Higuchi, Hideo
    Ohuchi, Noriaki
    FUTURE MEDICAL ENGINEERING BASED ON BIONANOTECHNOLOGY, PROCEEDINGS, 2006, : 395 - +
  • [7] Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
    Valabrega, G.
    Montemurro, F.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 977 - 984
  • [8] Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    Shattuck, David L.
    Miller, Jamie K.
    Carraway, Kermit L., III
    Sweeney, Colleen
    CANCER RESEARCH, 2008, 68 (05) : 1471 - 1477
  • [9] Role of HSP27 in trastuzumab resistance in HER2-overexpressing breast cancer
    Hwang, S-Y.
    Choi, S-K.
    Na, Y.
    Lee, Y-S.
    Kwon, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 24 - 24
  • [10] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Clara Natoli
    Patrizia Vici
    Isabella Sperduti
    Antonino Grassadonia
    Giancarlo Bisagni
    Nicola Tinari
    Andrea Michelotti
    Germano Zampa
    Stefania Gori
    Luca Moscetti
    Michele De Tursi
    Michele Panebianco
    Maria Mauri
    Ilaria Ferrarini
    Laura Pizzuti
    Corrado Ficorella
    Riccardo Samaritani
    Lucia Mentuccia
    Stefano Iacobelli
    Teresa Gamucci
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1229 - 1240
12345